Aggrastat (tirofiban HCl)
Drug Acute cardiovascular care.
NDC 25208-002-02
General payments
$8,321
Research payments
$58,054
Through program year 2019, $8,321 in general payments and $58,054 in research payments were reported against Aggrastat (tirofiban HCl) (Acute cardiovascular care.).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | General | $8,321 | 16 |
| 2019 | Research | $58,054 | 2 |
Breakdown
The top 5 of 14 recipients; each share is of general payments naming this product in 2019.
The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2019 where a state was reported.
Records
16 general · 2 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.